Jan. 06, 2026 -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare Conference, to take place January 12-15, 2026, in San Francisco, California. Mapi is actively seeking new partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the J.P. Morgan Healthca

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed th

As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Jan. 08, 2026 -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the brand name NASARIX™. NASARIX™ is based on Polyrizon’s proprietary Cap

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and acne are the two most commonly diagnosed skin disorders in the US1 Jan. 08, 2026 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database

Jan. 08, 2026 -- Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating KYZATREX® (testosterone undecanoate) CIII capsules in men ages 65–80 with hypogonadism. KYZATREX is a prescription drug used to treat adult men who have low or no testosterone levels due to certain medical conditions. As men age, the effects of low testosterone can intersect with broader age-related changes, influencing energy, mob

– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction and overdose – – With Dual NMR agonists, NOP and MOP agonism combine to provide analgesia while NOP counters many of the negative effects of MOP receptor agonism – – Dual NOP-MOP agonists have the potential to provide comparable analgesia, but with a substantially lower risk of abuse, addiction, and overdose than preferential MOP agonis

Jan. 09, 2026 -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical cognitive conditions — along with MRI and PET images in Bio-Hermes-002 —as well as numerous races and ethnicities to gener

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates. Restores global TDP-43 splicing function in disease-relevant systems. Demonstrates in vivo activity in multiple animal models with biomarker readouts supportive of disease modification. Potential applicability across TDP-43 proteinopathies including Traumatic Brain Injury and Frontotemporal Dementia. Jan. 08, 2026 -- Dewpoint Therapeutics, Inc., a clinical-stage biotechnology comp

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026 Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Autoimmune Dis

Jan. 07, 2026 -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing the investigational product, inhaled opelconazole, for patients suffering from serious acute and chronic respiratory diseases, today announced the decision to terminate its Opera-T Phase 3 Study with opelconazole in refractory Invasive Pulmonary Aspergillosis (IPA). This decision was based on an interim analysis for the purpose of a sample size recalculation when approximately 50% of the subjects